Jane Street’s Protalix BioTherapeutics PLX Stock Holding History

Jane Street’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$126K	Buy	+58,000	New	+$144K	﹤0.01%	10504
2024 Q1	–	Sell	-17,100	Closed	-$30.4K	–	9885
2023 Q4	$30.4K	Hold	17,100	–	–	﹤0.01%	8864
2023 Q3	$28.4K	Sell	17,100 -17,500	-51%	-$31.4K	﹤0.01%	8257
2023 Q2	$69.2K	Buy	+34,600	New	+$82.4K	﹤0.01%	8136
2021 Q4	–	Sell	-119,600	Closed	-$159K	–	10652
2021 Q3	$159K	Sell	119,600 -51,600	-30%	-$78.4K	﹤0.01%	9022
2021 Q2	$327K	Buy	171,200 +140,100	+450%	+$482K	﹤0.01%	8001
2021 Q1	$139K	Buy	+31,100	New	+$145K	﹤0.01%	8497

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MCO

MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SWP

Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

PFS

Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Jane Street's PLX Position: Q1 2026 in Review

Jane Street reduced its Protalix BioTherapeutics (PLX) stake by 94% in Q1 2026, selling an estimated $676K and leaving 17,342 shares worth $37.6K. The position accounts for ﹤0.01% of the portfolio, ranked #11060.

Jane Street first reported a position in PLX in Q2 2013 and has held it in 47 quarters since. The position peaked at $753K in Q1 2025. 99 funds tracked by Wall St. Rank hold PLX as of Q1 2026.

Jane Street held 17,342 shares of Protalix BioTherapeutics worth $37.6K as of Q1 2026.
Jane Street sold 272,575 Protalix BioTherapeutics shares in Q1 2026, an estimated $676K.
Protalix BioTherapeutics made up ﹤0.01% of Jane Street's portfolio in Q1 2026, its #11060 holding.
Jane Street first reported a position in Protalix BioTherapeutics in Q2 2013 and has held it in 47 quarters since.
Jane Street's Protalix BioTherapeutics position peaked at $753K in Q1 2025.
99 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.